Royce & Associates LP Reduces Stake in MiMedx Group, Inc. (NASDAQ:MDXG)

Royce & Associates LP lessened its stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 9.6% in the fourth quarter, Holdings Channel reports. The institutional investor owned 879,627 shares of the company’s stock after selling 93,226 shares during the quarter. Royce & Associates LP’s holdings in MiMedx Group were worth $8,462,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Van ECK Associates Corp purchased a new position in MiMedx Group during the fourth quarter valued at approximately $40,000. Point72 DIFC Ltd grew its position in shares of MiMedx Group by 127.6% during the 3rd quarter. Point72 DIFC Ltd now owns 7,626 shares of the company’s stock valued at $45,000 after purchasing an additional 4,275 shares in the last quarter. Orion Capital Management LLC increased its holdings in shares of MiMedx Group by 46.3% in the third quarter. Orion Capital Management LLC now owns 11,700 shares of the company’s stock worth $69,000 after purchasing an additional 3,700 shares during the period. SkyView Investment Advisors LLC increased its holdings in shares of MiMedx Group by 30.0% in the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the company’s stock worth $77,000 after purchasing an additional 3,000 shares during the period. Finally, AlphaQuest LLC purchased a new stake in shares of MiMedx Group in the fourth quarter worth $88,000. 79.15% of the stock is currently owned by institutional investors.

Insider Activity at MiMedx Group

In other MiMedx Group news, insider Kimberly Maersk-Moller sold 4,106 shares of the business’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $32,396.34. Following the transaction, the insider now owns 310,836 shares in the company, valued at approximately $2,452,496.04. The trade was a 1.30 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO William Frank Iv Hulse sold 81,446 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $7.80, for a total transaction of $635,278.80. Following the sale, the chief accounting officer now owns 494,774 shares of the company’s stock, valued at approximately $3,859,237.20. This represents a 14.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 142,259 shares of company stock worth $1,116,170 in the last ninety days. 1.30% of the stock is owned by company insiders.

MiMedx Group Trading Down 1.5 %

MDXG stock opened at $7.92 on Wednesday. MiMedx Group, Inc. has a one year low of $5.47 and a one year high of $10.14. The company has a market capitalization of $1.17 billion, a PE ratio of 14.40 and a beta of 1.97. The company’s 50 day moving average price is $8.42 and its two-hundred day moving average price is $7.84. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, hitting the consensus estimate of $0.07. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The business had revenue of $92.91 million during the quarter, compared to the consensus estimate of $89.42 million. As a group, analysts predict that MiMedx Group, Inc. will post 0.3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 target price on shares of MiMedx Group in a research note on Thursday, February 27th.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.